XLV stock forecast, quote, news & analysis
The investment seeks investment results that, before expenses, correspond generally to the price and yield performance of publicly traded equity securities of companies in the Health Care Select Sector Index... Show more
Why Health Care Select Sector SPDR Fund (XLV) Is Up +11% in the Last 30 Days
Key Takeaways
- The Health Care Select Sector SPDR Fund (XLV) gained roughly 11% over the trailing 30 days, climbing from about $166 to approximately $184.60 per share.
- The fund also advanced about 14% over the trailing quarter, signaling a broad and sustained health care rally rather than a short-lived spike.
- Performance was top-heavy: Eli Lilly, the fund's largest holding at roughly 15% of assets, was a principal driver of the move.
- Large-cap pharmaceutical, biotechnology, and health care equipment leadership, combined with defensive sector rotation, underpinned the advance.
- The fund's low 0.08% expense ratio and market-cap-weighted, roughly 60-holding structure concentrated the impact of its biggest names.
- Explore additional Price Targets and a detailed Forecast on the fund's dedicated pages.
- Discover momentum, breakout, and rotation candidates using Trending AI Robots.
Health Care Select Sector SPDR Fund (XLV) Overview and Portfolio Exposure
The Health Care Select Sector SPDR Fund is an exchange-traded fund (ETF) that seeks to track the price and yield performance of the Health Care Select Sector Index, a market-cap-weighted basket of health care companies drawn from the S&P 500. The fund uses a passive, replication-based strategy, generally investing at least 95% of assets in the securities of the underlying index.
As of the most recent reporting, XLV held roughly 60 to 64 securities with assets under management (AUM) exceeding $45 billion. The portfolio is heavily concentrated in large-cap names, with the top ten holdings representing about 60% of assets. The largest positions are Eli Lilly, Johnson & Johnson, AbbVie, UnitedHealth Group, and Merck, followed by Thermo Fisher Scientific, Amgen, Gilead Sciences, Abbott Laboratories, and Pfizer. By industry, pharmaceuticals, health care equipment and supplies, health care providers and services, biotechnology, and life sciences tools and services dominate the portfolio. The fund carries a 0.08% expense ratio.
Health Care Select Sector SPDR Fund (XLV) Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, XLV rose roughly 11%, advancing from about $166 in early October to roughly $184.60. The move was trend-driven rather than erratic, with steady gains early in the period that accelerated through mid-to-late October as buying broadened across the sector's largest constituents.
The trailing quarter tells a similar but stronger story. From an early-August level near $162, the fund climbed roughly 14% to its current price. The quarter featured an initial August surge, a September consolidation, and a decisive October breakout, indicating persistent demand rather than a single catalyst-driven spike.
What Drove XLV Price in the Last 30 Days
The recent advance was led by the fund's most heavily weighted holdings. With roughly 15% of assets, Eli Lilly exerts outsized influence, and strength in large-cap pharmaceutical and biotechnology leadership translated directly into fund performance. Johnson & Johnson and AbbVie, together about 17% of assets, further reinforced the upside.
Broader market dynamics also contributed. Health care's defensive, relatively stable earnings profile attracted capital as investors rotated toward quality amid ongoing uncertainty around monetary policy and economic growth. Elevated investor focus on the weight-loss (GLP-1) and broader pharmaceutical innovation themes supported sentiment toward the sector's largest drugmakers, while solid earnings and steady demand across providers and equipment names provided a stable foundation.
What Drove XLV Performance Over the Last Quarter
Over the trailing three months, the fund's roughly 14% gain reflected a sustained rotation into health care equities. The sector's large-cap bias, low beta relative to the broader market, and resilient earnings growth made it an attractive destination for institutional flows during a period of broader index volatility.
Pharmaceutical and biotechnology leadership, anchored by the fund's top holdings, drove most of the appreciation. The market-cap-weighted structure meant gains in names such as Eli Lilly, AbbVie, and Merck disproportionately lifted the fund, while more defensive providers and equipment stocks added stability. This combination of cyclical innovation themes and defensive characteristics defined the quarter's upward trend.
AI Screener
Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps investors scan thousands of securities using technical indicators, fundamentals, volatility metrics, price patterns, industry filters, AI-generated signals, and performance characteristics. The platform is designed to surface trending securities, breakout candidates, and new trading opportunities more efficiently than manual screening, allowing users to filter the market by the criteria most relevant to their strategy. For investors seeking a data-driven way to identify momentum and rotation candidates across the health care sector and beyond, the AI Screener offers a practical starting point for further research.
XLV ETF Outlook: What Investors Should Watch Next
Looking ahead, several factors are likely to shape the fund's path. Interest rate expectations and inflation trends remain central, as health care's longer-duration, growth-oriented names are sensitive to changes in the discount rate applied to future earnings. The earnings trajectory of the fund's largest holdings, particularly Eli Lilly and Johnson & Johnson, will be a key swing factor given their combined weight.
Investors should also monitor pharmaceutical pipeline developments, weight-loss drug commercialization, and regulatory and pricing policy, which can shift sentiment across the sector. Broader capital flows into defensive versus cyclical equities, sector rotation dynamics, and institutional positioning will influence demand. While the fund's diversification and defensive characteristics provide a degree of stability, concentration in a handful of mega-cap names means single-stock events can still move the entire ETF meaningfully.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
XLV's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for XLV turned positive on October 09, 2026. Looking at past instances where XLV's MACD turned positive, the stock continued to rise in 42 of 48 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on XLV as a result. In 82 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
XLV moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for XLV crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Following a +2.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in 263 of 324 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 230 of 271 cases where XLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for XLV moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 27 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 67 cases where XLV's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
XLV broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement